Baishnab Suman, Jaura Ravinder Singh, Sharma Saksham, Garg Honey, Singh Thakur Gurjeet
Department of Pharmacy Practice, Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Curr Diabetes Rev. 2024;20(8):12-22. doi: 10.2174/0115733998246567230924134603.
Pharmacoeconomics is an important tool for investigating and restructuring healthcare policies. In India, recent statistical studies have shown that the number of diabetic patients is rapidly increasing in the rural, middle and upper-class settings. The aim of this review is to call attention towards the need to carry out pharmacoeconomic studies for diabetes mellitus and highlight the outcome of these studies on healthcare. A well-structured literature search from PubMed, Embase, Springer, ScienceDirect, and Cochrane was done. Studies that evaluated the cost-effectiveness of various anti-diabetic agents for type 2 diabetes were eligible for inclusion in the analysis and review. Two independent reviewers sequentially assessed the titles, abstracts, and full articles to select studies that met the predetermined inclusion and exclusion criteria for data abstraction. Any discrepancies between the reviewers were resolved through consensus. By employing search terms such as pharmacoeconomics, diabetes mellitus, cost-effective analysis, cost minimization analysis, cost-utility analysis, and cost-benefit analysis, a total of 194 papers were gathered. Out of these, 110 papers were selected as they aligned with the defined search criteria and underwent the removal of duplicate entries. This review outlined four basic pharmacoeconomic studies carried out on diabetes mellitus. It gave a direction that early detection, patient counseling, personalized medication, appropriate screening intervals, and early start of pharmacotherapy proved to be a cost-effective as well as health benefits approach.
药物经济学是研究和调整医疗保健政策的重要工具。在印度，最近的统计研究表明，农村、中产阶级和上层阶级环境中糖尿病患者的数量正在迅速增加。本综述的目的是呼吁关注开展糖尿病药物经济学研究的必要性，并强调这些研究对医疗保健的结果。我们从PubMed、Embase、Springer、ScienceDirect和Cochrane进行了结构良好的文献检索。评估各种抗糖尿病药物治疗2型糖尿病成本效益的研究有资格纳入分析和综述。两名独立评审员依次评估标题、摘要和全文，以选择符合预定纳入和排除标准的数据提取研究。评审员之间的任何差异都通过协商一致解决。通过使用药物经济学、糖尿病、成本效益分析、成本最小化分析、成本效用分析和成本效益分析等搜索词，共收集了194篇论文。其中，110篇论文因符合定义的搜索标准而被选中，并进行了重复条目删除。本综述概述了对糖尿病进行的四项基本药物经济学研究。它给出了一个方向，即早期检测、患者咨询、个性化用药、适当的筛查间隔和早期开始药物治疗被证明是一种具有成本效益且有益健康的方法。
